Sanofi SA banner

Sanofi SA
XBER:SNW

Watchlist Manager
Sanofi SA Logo
Sanofi SA
XBER:SNW
Watchlist
Price: 82.48 EUR Market Closed
Market Cap: €103.2B

EV/EBIT

10.5
Current
9%
Cheaper
vs 3-y average of 11.5

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
10.5
=
Enterprise Value
€106.6B
/
EBIT
€10.1B

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
10.5
=
Enterprise Value
€106.6B
/
EBIT
€10.1B

Valuation Scenarios

Sanofi SA is trading below its 3-year average

If EV/EBIT returns to its 3-Year Average (11.5), the stock would be worth €90.57 (10% upside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
-38%
Maximum Upside
+27%
Average Upside
6%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 10.5 €82.48
0%
3-Year Average 11.5 €90.57
+10%
5-Year Average 13.1 €103.33
+25%
Industry Average 6.5 €51.3
-38%
Country Average 13.2 €104.55
+27%

Forward EV/EBIT
Today’s price vs future ebit

Today's Enterprise Value EBIT Forward EV/EBIT
€106.6B
/
Jan 2026
€10.1B
=
10.5
Current
€106.6B
/
Dec 2026
€12.3B
=
8.6
Forward
€106.6B
/
Dec 2027
€13B
=
8.2
Forward
€106.6B
/
Dec 2028
€14.1B
=
7.5
Forward

Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close
Market Cap EV/EBIT P/E
FR
Sanofi SA
XBER:SNW
97.9B EUR 10.5 12.5
US
Eli Lilly and Co
NYSE:LLY
870.6B USD 30.4 42.2
US
Johnson & Johnson
NYSE:JNJ
544.4B USD 21.2 25.9
CH
Roche Holding AG
SIX:ROG
248.4B CHF 13.1 19.6
UK
AstraZeneca PLC
LSE:AZN
225.4B GBP 22.8 29.2
CH
Novartis AG
SIX:NOVN
222.8B CHF 15.9 20
US
Merck & Co Inc
NYSE:MRK
279.4B USD 11.6 15.3
IE
Endo International PLC
LSE:0Y5F
244.4B USD 970 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 9.4 10.8
US
Pfizer Inc
NYSE:PFE
152.4B USD 10.1 19.6
US
Bristol-Myers Squibb Co
NYSE:BMY
118.4B USD 8.8 16.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
Sanofi SA
XBER:SNW
Average EV/EBIT: 102.2
10.5
12%
0.9
US
Eli Lilly and Co
NYSE:LLY
30.4
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
21.2
13%
1.6
CH
Roche Holding AG
SIX:ROG
13.1
6%
2.2
UK
AstraZeneca PLC
LSE:AZN
22.8
21%
1.1
CH
Novartis AG
SIX:NOVN
15.9
9%
1.8
US
Merck & Co Inc
NYSE:MRK
11.6
6%
1.9
IE
E
Endo International PLC
LSE:0Y5F
970
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.4
2%
4.7
US
Pfizer Inc
NYSE:PFE
10.1
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-7%
N/A
P/E Multiple
Earnings Growth PEG
FR
Sanofi SA
XBER:SNW
Average P/E: 21.2
12.5
16%
0.8
US
Eli Lilly and Co
NYSE:LLY
42.2
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
25.9
8%
3.2
CH
Roche Holding AG
SIX:ROG
19.6
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
29.2
25%
1.2
CH
Novartis AG
SIX:NOVN
20
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.3
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.6
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

In line with most companies in France
Percentile
40th
Based on 1 432 companies
40th percentile
10.6
Low
0 — 9.5
Typical Range
9.5 — 17.5
High
17.5 —
Distribution Statistics
France
Min 0
30th Percentile 9.5
Median 13.2
70th Percentile 17.5
Max 1 862.3

Sanofi SA
Glance View

Sanofi SA, a titan in the global healthcare sector, operates at the intricate crossroads of pharmaceutical innovation and patient care, driven by an unyielding commitment to improving human health. Emerging from its French roots, Sanofi has strategically positioned itself as a global leader in pharmaceuticals, vaccines, and consumer healthcare. The company’s success is essentially anchored in its capacity to consistently develop and commercialize life-saving drugs that address a myriad of health concerns, ranging from diabetes and cardiovascular diseases to rare disorders and oncology. Underlining its robust revenue engine is Sanofi's extensive R&D infrastructure that fuels its pipeline with groundbreaking therapies, reflecting a dynamic blend of scientific acumen and market-focused agility. By leveraging a hybrid model that integrates cutting-edge research with strategic alliances and acquisitions, Sanofi ensures a sustained presence in the highly competitive biopharmaceutical landscape. Enabling this network of innovation and impact is Sanofi's diverse portfolio, a balanced mix of specialty and established prescription drugs, over-the-counter products, and the critical arm of vaccines led by its Sanofi Pasteur division. This diversification offers both growth opportunities and stability, cushioning against the volatile tides of patent expirations and regulatory changes. Its vaccines segment, in particular, is a cornerstone in Sanofi's business, capturing substantial market share with products critical to global immunization efforts, further amplified by its role in responding to health emergencies like the COVID-19 pandemic. With a geographically expansive sales footprint and strategic marketing strategies, Sanofi capitalizes on emerging market opportunities while maintaining a strong presence in established regions, effectively making its bottom line a testimony to its operational excellence and strategic foresight in harmonizing science with humanity.

SNW Intrinsic Value
164.54 EUR
Undervaluation 50%
Intrinsic Value
Price €82.48
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett